Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries
Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in complex native-vessel lesions at high risk for restenosis. Angiographic follow-up at 240 days was obtained in 701 patients with long...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2004-12, Vol.110 (25), p.3773-3780 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3780 |
|---|---|
| container_issue | 25 |
| container_start_page | 3773 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 110 |
| creator | POPMA, Jeffrey J LEON, Martin B KUNTZ, Richard E MOSES, Jeffrey W HOLMES, David R COX, Nicholas FITZPATRICK, Michelle DOUGLAS, John LAMBERT, Charles MOONEY, Michael YAKUBOV, Steven |
| description | Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in complex native-vessel lesions at high risk for restenosis.
Angiographic follow-up at 240 days was obtained in 701 patients with long (15- to 25-mm) lesions in small-diameter (2.5- to 3.5-mm) native vessels who were randomly assigned to treatment with SESs or bare-metal stents (BMSs) in the SIRIUS trial. Quantitative angiographic measurements of minimal lumen diameter and percent diameter stenosis were obtained within the treated segment, within the stent, and within its 5-mm proximal and distal edges. Patients treated with SESs had lower rates of binary (>50% diameter stenosis) angiographic restenosis within the segment (8.9% versus 36.3% with the BMS; P |
| doi_str_mv | 10.1161/01.CIR.0000150331.14687.4B |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67193885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67193885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-d9fb409aae52cf7db2fd52a3cedaaa86720a2403c31956865717d693f16bedec3</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYNY7Fr9ChIEfZsxfybJxDe7VC0UiqLP4W4ms0ZmkjV3Rui3N-0u7KN5uQR-59x7OIS85azlXPMPjLfb2-8tq48rJiVvead703bXz8iGK9E1nZL2OdlUwDZGCnFJXiL-rl8tjXpBLrlSVivdb8jDtxXSEhdY4t9AATEgziEtNI8U0j7mfYHDr-hpCbiElDEihXEJhWIseYrzik2Y1iWmPX0EFhrnw1Qtq2FONCaajtY-l5ygPFAoVR0DviIXI0wYXp_mFfn5-ebH9mtzd__ldvvprvE1xNIMdtx1zAIEJfxohp0YByVA-jAAQK-NYCA6Jr3ktibSynAzaCtHrndhCF5ekfdH30PJf9aaws0RfZjqkSGv6LThVva9-i_IrZVGS1bBj0fQl4xYwugOJc41m-PMPTbkGHe1IXduyD015LrrKn5z2rLu5jCcpadKKvDuBAB6mMYCyUc8c1oJ1Sst_wG9I54g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19937630</pqid></control><display><type>article</type><title>Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>POPMA, Jeffrey J ; LEON, Martin B ; KUNTZ, Richard E ; MOSES, Jeffrey W ; HOLMES, David R ; COX, Nicholas ; FITZPATRICK, Michelle ; DOUGLAS, John ; LAMBERT, Charles ; MOONEY, Michael ; YAKUBOV, Steven</creator><creatorcontrib>POPMA, Jeffrey J ; LEON, Martin B ; KUNTZ, Richard E ; MOSES, Jeffrey W ; HOLMES, David R ; COX, Nicholas ; FITZPATRICK, Michelle ; DOUGLAS, John ; LAMBERT, Charles ; MOONEY, Michael ; YAKUBOV, Steven ; SIRIUS Investigators</creatorcontrib><description>Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in complex native-vessel lesions at high risk for restenosis.
Angiographic follow-up at 240 days was obtained in 701 patients with long (15- to 25-mm) lesions in small-diameter (2.5- to 3.5-mm) native vessels who were randomly assigned to treatment with SESs or bare-metal stents (BMSs) in the SIRIUS trial. Quantitative angiographic measurements of minimal lumen diameter and percent diameter stenosis were obtained within the treated segment, within the stent, and within its 5-mm proximal and distal edges. Patients treated with SESs had lower rates of binary (>50% diameter stenosis) angiographic restenosis within the segment (8.9% versus 36.3% with the BMS; P<0.001) and within the stent (3.2% versus 35.4% with the BMS; P<0.001). SESs were associated with significantly less late lumen loss within the treated segment, within the stent, and within its 5-mm proximal and distal edges (all P<0.001). The reduction of restenosis with the SES was consistent in patients at risk for restenosis, including those with small vessels, long lesions, and diabetes mellitus. The frequency of late aneurysms was similar in the 2 groups.
Compared with BMSs, SESs reduced angiographic late lumen loss within the stent and its adjacent 5-mm margins in patients with complex native-vessel lesions.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.0000150331.14687.4B</identifier><identifier>PMID: 15596568</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Coronary Aneurysm - diagnostic imaging ; Coronary Aneurysm - epidemiology ; Coronary Angiography ; Coronary heart disease ; Coronary Restenosis - diagnostic imaging ; Coronary Restenosis - etiology ; Coronary Restenosis - prevention & control ; Coronary Stenosis - therapy ; Diabetes Complications - therapy ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Double-Blind Method ; Drug Implants ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Heart ; Heparin - therapeutic use ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Randomized Controlled Trials as Topic ; Sirolimus - administration & dosage ; Sirolimus - therapeutic use ; Stents ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the heart ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use ; Treatment Outcome</subject><ispartof>Circulation (New York, N.Y.), 2004-12, Vol.110 (25), p.3773-3780</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-d9fb409aae52cf7db2fd52a3cedaaa86720a2403c31956865717d693f16bedec3</citedby><cites>FETCH-LOGICAL-c539t-d9fb409aae52cf7db2fd52a3cedaaa86720a2403c31956865717d693f16bedec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16525856$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15596568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POPMA, Jeffrey J</creatorcontrib><creatorcontrib>LEON, Martin B</creatorcontrib><creatorcontrib>KUNTZ, Richard E</creatorcontrib><creatorcontrib>MOSES, Jeffrey W</creatorcontrib><creatorcontrib>HOLMES, David R</creatorcontrib><creatorcontrib>COX, Nicholas</creatorcontrib><creatorcontrib>FITZPATRICK, Michelle</creatorcontrib><creatorcontrib>DOUGLAS, John</creatorcontrib><creatorcontrib>LAMBERT, Charles</creatorcontrib><creatorcontrib>MOONEY, Michael</creatorcontrib><creatorcontrib>YAKUBOV, Steven</creatorcontrib><creatorcontrib>SIRIUS Investigators</creatorcontrib><title>Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in complex native-vessel lesions at high risk for restenosis.
Angiographic follow-up at 240 days was obtained in 701 patients with long (15- to 25-mm) lesions in small-diameter (2.5- to 3.5-mm) native vessels who were randomly assigned to treatment with SESs or bare-metal stents (BMSs) in the SIRIUS trial. Quantitative angiographic measurements of minimal lumen diameter and percent diameter stenosis were obtained within the treated segment, within the stent, and within its 5-mm proximal and distal edges. Patients treated with SESs had lower rates of binary (>50% diameter stenosis) angiographic restenosis within the segment (8.9% versus 36.3% with the BMS; P<0.001) and within the stent (3.2% versus 35.4% with the BMS; P<0.001). SESs were associated with significantly less late lumen loss within the treated segment, within the stent, and within its 5-mm proximal and distal edges (all P<0.001). The reduction of restenosis with the SES was consistent in patients at risk for restenosis, including those with small vessels, long lesions, and diabetes mellitus. The frequency of late aneurysms was similar in the 2 groups.
Compared with BMSs, SESs reduced angiographic late lumen loss within the stent and its adjacent 5-mm margins in patients with complex native-vessel lesions.</description><subject>Aged</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Coronary Aneurysm - diagnostic imaging</subject><subject>Coronary Aneurysm - epidemiology</subject><subject>Coronary Angiography</subject><subject>Coronary heart disease</subject><subject>Coronary Restenosis - diagnostic imaging</subject><subject>Coronary Restenosis - etiology</subject><subject>Coronary Restenosis - prevention & control</subject><subject>Coronary Stenosis - therapy</subject><subject>Diabetes Complications - therapy</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Double-Blind Method</subject><subject>Drug Implants</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heparin - therapeutic use</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Sirolimus - administration & dosage</subject><subject>Sirolimus - therapeutic use</subject><subject>Stents</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the heart</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV9rFDEUxYNY7Fr9ChIEfZsxfybJxDe7VC0UiqLP4W4ms0ZmkjV3Rui3N-0u7KN5uQR-59x7OIS85azlXPMPjLfb2-8tq48rJiVvead703bXz8iGK9E1nZL2OdlUwDZGCnFJXiL-rl8tjXpBLrlSVivdb8jDtxXSEhdY4t9AATEgziEtNI8U0j7mfYHDr-hpCbiElDEihXEJhWIseYrzik2Y1iWmPX0EFhrnw1Qtq2FONCaajtY-l5ygPFAoVR0DviIXI0wYXp_mFfn5-ebH9mtzd__ldvvprvE1xNIMdtx1zAIEJfxohp0YByVA-jAAQK-NYCA6Jr3ktibSynAzaCtHrndhCF5ekfdH30PJf9aaws0RfZjqkSGv6LThVva9-i_IrZVGS1bBj0fQl4xYwugOJc41m-PMPTbkGHe1IXduyD015LrrKn5z2rLu5jCcpadKKvDuBAB6mMYCyUc8c1oJ1Sst_wG9I54g</recordid><startdate>20041221</startdate><enddate>20041221</enddate><creator>POPMA, Jeffrey J</creator><creator>LEON, Martin B</creator><creator>KUNTZ, Richard E</creator><creator>MOSES, Jeffrey W</creator><creator>HOLMES, David R</creator><creator>COX, Nicholas</creator><creator>FITZPATRICK, Michelle</creator><creator>DOUGLAS, John</creator><creator>LAMBERT, Charles</creator><creator>MOONEY, Michael</creator><creator>YAKUBOV, Steven</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20041221</creationdate><title>Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries</title><author>POPMA, Jeffrey J ; LEON, Martin B ; KUNTZ, Richard E ; MOSES, Jeffrey W ; HOLMES, David R ; COX, Nicholas ; FITZPATRICK, Michelle ; DOUGLAS, John ; LAMBERT, Charles ; MOONEY, Michael ; YAKUBOV, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-d9fb409aae52cf7db2fd52a3cedaaa86720a2403c31956865717d693f16bedec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Coronary Aneurysm - diagnostic imaging</topic><topic>Coronary Aneurysm - epidemiology</topic><topic>Coronary Angiography</topic><topic>Coronary heart disease</topic><topic>Coronary Restenosis - diagnostic imaging</topic><topic>Coronary Restenosis - etiology</topic><topic>Coronary Restenosis - prevention & control</topic><topic>Coronary Stenosis - therapy</topic><topic>Diabetes Complications - therapy</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Double-Blind Method</topic><topic>Drug Implants</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heparin - therapeutic use</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Sirolimus - administration & dosage</topic><topic>Sirolimus - therapeutic use</topic><topic>Stents</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the heart</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POPMA, Jeffrey J</creatorcontrib><creatorcontrib>LEON, Martin B</creatorcontrib><creatorcontrib>KUNTZ, Richard E</creatorcontrib><creatorcontrib>MOSES, Jeffrey W</creatorcontrib><creatorcontrib>HOLMES, David R</creatorcontrib><creatorcontrib>COX, Nicholas</creatorcontrib><creatorcontrib>FITZPATRICK, Michelle</creatorcontrib><creatorcontrib>DOUGLAS, John</creatorcontrib><creatorcontrib>LAMBERT, Charles</creatorcontrib><creatorcontrib>MOONEY, Michael</creatorcontrib><creatorcontrib>YAKUBOV, Steven</creatorcontrib><creatorcontrib>SIRIUS Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POPMA, Jeffrey J</au><au>LEON, Martin B</au><au>KUNTZ, Richard E</au><au>MOSES, Jeffrey W</au><au>HOLMES, David R</au><au>COX, Nicholas</au><au>FITZPATRICK, Michelle</au><au>DOUGLAS, John</au><au>LAMBERT, Charles</au><au>MOONEY, Michael</au><au>YAKUBOV, Steven</au><aucorp>SIRIUS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2004-12-21</date><risdate>2004</risdate><volume>110</volume><issue>25</issue><spage>3773</spage><epage>3780</epage><pages>3773-3780</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in complex native-vessel lesions at high risk for restenosis.
Angiographic follow-up at 240 days was obtained in 701 patients with long (15- to 25-mm) lesions in small-diameter (2.5- to 3.5-mm) native vessels who were randomly assigned to treatment with SESs or bare-metal stents (BMSs) in the SIRIUS trial. Quantitative angiographic measurements of minimal lumen diameter and percent diameter stenosis were obtained within the treated segment, within the stent, and within its 5-mm proximal and distal edges. Patients treated with SESs had lower rates of binary (>50% diameter stenosis) angiographic restenosis within the segment (8.9% versus 36.3% with the BMS; P<0.001) and within the stent (3.2% versus 35.4% with the BMS; P<0.001). SESs were associated with significantly less late lumen loss within the treated segment, within the stent, and within its 5-mm proximal and distal edges (all P<0.001). The reduction of restenosis with the SES was consistent in patients at risk for restenosis, including those with small vessels, long lesions, and diabetes mellitus. The frequency of late aneurysms was similar in the 2 groups.
Compared with BMSs, SESs reduced angiographic late lumen loss within the stent and its adjacent 5-mm margins in patients with complex native-vessel lesions.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15596568</pmid><doi>10.1161/01.CIR.0000150331.14687.4B</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2004-12, Vol.110 (25), p.3773-3780 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67193885 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aspirin - therapeutic use Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Coronary Aneurysm - diagnostic imaging Coronary Aneurysm - epidemiology Coronary Angiography Coronary heart disease Coronary Restenosis - diagnostic imaging Coronary Restenosis - etiology Coronary Restenosis - prevention & control Coronary Stenosis - therapy Diabetes Complications - therapy Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Double-Blind Method Drug Implants Drug Therapy, Combination Female Follow-Up Studies Heart Heparin - therapeutic use Humans Incidence Male Medical sciences Middle Aged Randomized Controlled Trials as Topic Sirolimus - administration & dosage Sirolimus - therapeutic use Stents Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome |
| title | Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A40%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantitative%20assessment%20of%20angiographic%20restenosis%20after%20sirolimus-eluting%20stent%20implantation%20in%20native%20coronary%20arteries&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=POPMA,%20Jeffrey%20J&rft.aucorp=SIRIUS%20Investigators&rft.date=2004-12-21&rft.volume=110&rft.issue=25&rft.spage=3773&rft.epage=3780&rft.pages=3773-3780&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.0000150331.14687.4B&rft_dat=%3Cproquest_cross%3E67193885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19937630&rft_id=info:pmid/15596568&rfr_iscdi=true |